ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare

Lung Cancer

Volumn 94, Issue , 2016, Pages 22-27

  Zhao, Weijie ^a   Choi, Yoon La ^b,c   Song, Ji Young ^b   Zhu, Yazhen ^d   Xu, Qing ^a   Zhang, Feng ^a   Jiang, Lili ^a   Cheng, Ju ^a   Zheng, Guangjuan ^d   Mao, Mao ^a  

^a WUXI APPTEC   (China)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Anaplastic lymphoma kinase; Fusion; Squamous cell carcinoma

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; PROTEIN; PROTEIN P63; PROTEIN RET; ROS1 PROTEIN; THYROID TRANSCRIPTION FACTOR 1; UNCLASSIFIED DRUG; ONCOPROTEIN; PROTEIN TYROSINE KINASE; ROS1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ASSAY; CANCER DIAGNOSIS; CANCER SURGERY; CHROMOSOME TRANSLOCATION; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE FUSION; GENE OVEREXPRESSION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NON SMALL CELL LUNG CANCER; PREVALENCE; PRIORITY JOURNAL; SQUAMOUS CELL LUNG CARCINOMA; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; FEMALE; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSCRIPTION, GENETIC; TRANSLOCATION, GENETIC;

EID: 84960393206     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.01.011     Document Type: Article

References (45)

1. Selinger C.I., Rogers T.M., Russell P.A., O'Toole S., Yip P., Wright G.M., et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod. Pathol. 2013, 26:1545-1553.
2. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics. CA Cancer J. Clin. 2006, 56:106-130.
3. Perez-Moreno P., Brambilla E., Thomas R., Soria J.C. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin. Cancer Res. 2012, 18:2443-2451.
4. Perner S., Wagner P.L., Demichelis F., Mehra R., Lafargue C.J., Moss B.J., et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia 2008, 10:298-302.
5. Solomon B., Varella-Garcia M., Camidge D.R. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J. Thorac. Oncol. 2009, 4:1450-1454.
6. Gainor J.F., Varghese A.M., Ou S.H., Kabraji S., Awad M.M., Katayama R., et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1683 patients with non-small cell lung cancer. Clin. Cancer Res. 2013, 19:4273-4281.
7. Ju Y.S., Lee W.C., Shin J.Y., Lee S., Bleazard T., Won J.K., et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012, 22:436-445.
8. Lipson D., Capelletti M., Yelensky R., Otto G., Parker A., Jarosz M., et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med. 2012, 18:382-384.
9. Takeuchi K., Soda M., Togashi Y., Suzuki R., Sakata S., Hatano S., et al. RET, ROS1 and ALK fusions in lung cancer. Nat. Med. 2012, 18:378-381.
10. Bergethon K., Shaw A.T., Ou S.H., Katayama R., Lovly C.M., McDonald N.T., et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 2012, 30:863-870.
11. Kohno T., Ichikawa H., Totoki Y., Yasuda K., Hiramoto M., Nammo T., et al. KIF5B-RET fusions in lung adenocarcinoma. Nat. Med. 2012, 18:375-377.
12. Davies K.D., Le A.T., Theodoro M.F., Skokan M.C., Aisner D.L., Berge E.M., et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin. Cancer Res. 2012, 18:4570-4579.
13. Wang R., Hu H., Pan Y., Li Y., Ye T., Li C., et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J. Clin. Oncol. 2012, 30:4352-4359.
14. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 2009, 27:4247-4253.
15. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
16. Lindeman N.I., Cagle P.T., Beasley M.B., Chitale D.A., Dacic S., Giaccone G., et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J. Thorac. Oncol. 2013, 8:823-859.
17. Boland J.M., Erdogan S., Vasmatzis G., Yang P., Tillmans L.S., Johnson M.R., et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum. Pathol. 2009, 40:1152-1158.
18. Inamura K., Takeuchi K., Togashi Y., Hatano S., Ninomiya H., Motoi N., et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod. Pathol. 2009, 22:508-515.
19. Koivunen J.P., Mermel C., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J., et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 2008, 14:4275-4283.
20. Salido M., Pijuan L., Martinez-Aviles L., Galvan A.B., Canadas I., Rovira A., et al. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J. Thorac. Oncol. 2011, 6:21-27.
21. Shinmura K., Kageyama S., Tao H., Bunai T., Suzuki M., Kamo T., et al. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 2008, 61:163-169.
22. Kim H., Yoo S.B., Choe J.Y., Paik J.H., Xu X., Nitta H., et al. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J. Thorac. Oncol. 2011, 6:1359-1366.
23. Takeuchi K., Choi Y.L., Soda M., Inamura K., Togashi Y., Hatano S., et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin. Cancer Res. 2008, 14:6618-6624.
24. Takahashi T., Sonobe M., Kobayashi M., Yoshizawa A., Menju T., Nakayama E., et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann. Surg. Oncol. 2010, 17:889-897.
25. Inamura K., Takeuchi K., Togashi Y., Nomura K., Ninomiya H., Okui M., et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J. Thorac. Oncol. 2008, 3:13-17.
26. Alrifai D., Popat S., Ahmed M., Gonzalez D., Nicholson A.G., Jd Parcq, et al. A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations. Lung Cancer 2013, 80:339-340.
27. Seto T., Kiura K., Nishio M., Nakagawa K., Maemondo M., Inoue A., et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol. 2013, 14:590-598.
28. Calio A., Nottegar A., Gilioli E., Bria E., Pilotto S., Peretti U., et al. ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung. J. Thorac. Oncol. 2014, 9:729-732.
29. Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131:1190-1203.
30. Camidge D.R., Bang Y.J., Kwak E.L., Iafrate A.J., Varella-Garcia M., Fox S.B., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012, 13:1011-1019.
31. Lira M.E., Choi Y.-L., Lim S.M., Deng S., Huang D., Ozeck M., et al. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer. J. Mol. Diagn. 2014, 16:229-243.
32. Fang D.D., Zhang B., Gu Q., Lira M., Xu Q., Sun H., et al. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib. J. Thorac. Oncol. 2014, 9:285-294.
33. Beasley M.B., Brambilla E., Travis W.D. The 2004 world health organization classification of lung tumors. Semin. Roentgenol. 2005, 40:90-97.
34. Lira M.E., Kim T.M., Huang D., Deng S., Koh Y., Jang B., et al. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. J. Mol. Diagn. 2013, 15:51-61.
35. Chaft J.E., Rekhtman N., Ladanyi M., Riely G.J. ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma. J. Thorac. Oncol. 2012, 7:768-769.
36. Li C., Hao L., Li Y., Wang S., Chen H., Zhang L., et al. Prognostic value analysis of mutational and clinicopathological factors in non-small cell lung cancer. PLoS One 2014, 9:e107276.
37. Tsuta K., Kohno T., Yoshida A., Shimada Y., Asamura H., Furuta K., et al. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis. Br. J. Cancer 2014, 110:1571-1578.
38. Just P.A., Cazes A., Audebourg A., Cessot A., Pallier K., Danel C., et al. Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers. Lung Cancer 2012, 76:309-315.
39. Lewis D.R., Check D.P., Caporaso N.E., Travis W.D., Devesa S.S. US lung cancer trends by histologic type. Cancer 2014, 120:2883-2892.
40. Kim H., Park E., Kim Y.J., Chung J.H. ALK rearrangement in a pure squamous cell carcinoma: the challenge of detection of ALK rearrangement. Virchows Arch. 2013, 462:597-599.
41. Ochi N., Yamane H., Yamagishi T., Takigawa N., Monobe Y. Can we eliminate squamous cell carcinoma of the lung from testing of EML4-ALK fusion gene. Lung Cancer 2013, 79:94-95.
42. Klempner S.J., Cohen D.W., Costa D.B. ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers. J. Thorac. Oncol. 2011, 6:1439-1440.
43. An S.J., Chen Z.H., Su J., Zhang X.C., Zhong W.Z., Yang J.J., et al. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One 2012, 7:e40109.
44. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010, 363:1693-1703.
45. Rimkunas V.M., Crosby K.E., Li D., Hu Y., Kelly M.E., Gu T.L., et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin. Cancer Res. 2012, 18:4449-4457.